EUVIMEDEUVIMED entdecken
Fallbericht

Elevated serum lipase in infants with cystic fibrosis exposed to prenatal and postnatal elexacaftor/tezacaftor/ivacaftor

Haley Haskett, Christopher Fortner, Laura Shanley, Clement L Ren

Journal of Cystic Fibrosis · 2025-11 · 24 (6) · 1090-1093

DOI: 10.1016/j.jcf.2025.07.013 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Cystic Fibrosis, 2025-11. Verfasst von Haley Haskett und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Electronic address: hasketth@chop.edu. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Benzodioxoles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction leads to progressive exocrine pancreatic insufficiency, resulting in difficulty in the secretion of digestive enzymes and subsequent malabsorption of nutrients. Case reports have described preserved pancreatic function with prenatal elexacaftor/tezacaftor/ivacaftor (ETI) exposure. However, little is known about pancreatic function and injury as ETI exposure decreases postnatally. Here, we discuss four infants with cystic fibrosis (CF) who were prenatally exposed to ETI, with pancreatic function ranging from preserved to mild insufficiency. All four developed elevated serum lipase, a marker of pancreatic cell injury, as ETI exposure diminished after birth. These cases illustrate the relationship between sweat chloride as a biomarker of CFTR function, fecal elastase as a biomarker of pancreatic function, and serum lipase a biomarker of pancreatic cell injury. While prenatal ETI exposure can preserve pancreatic function in infants with CF, ongoing postnatal ETI exposure may be necessary to prevent pancreatic damage, suggesting a role for early ETI therapy in prenatally exposed infants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsQuinolonesBenzodioxolesLipasePrenatal Exposure Delayed EffectsIndolesPyrazolesHumansFemalePregnancyMaleDrug CombinationsInfant, NewbornInfantChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorPyridinesPyrrolidines

Stichwörter der Autor:innen

CFTR modulatorsFetal therapyPancreatic cell injuryPancreatitis

Substanzen

AminophenolsQuinolonesBenzodioxolesLipaseDrug CombinationsIndolesChloride Channel AgonistsPyrazolesCystic Fibrosis Transmembrane Conductance RegulatorPyridines

Autor:innen und Institutionen

  • Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Electronic address: hasketth@chop.edu.
  • Division of Pulmonary and Sleep Medicine, SUNY Upstate Medical Center, Syracuse, NY, USA.
  • Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Förderung

  • Cystic Fibrosis Foundation

Zitieren

APA

Haskett, H., Fortner, C., Shanley, L., & Ren, C. L. (2025). Elevated serum lipase in infants with cystic fibrosis exposed to prenatal and postnatal elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis, 24(6), 1090-1093. https://doi.org/10.1016/j.jcf.2025.07.013

Vancouver

Haskett H, Fortner C, Shanley L, Ren CL. Elevated serum lipase in infants with cystic fibrosis exposed to prenatal and postnatal elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis. 2025;24(6):1090-1093. doi:10.1016/j.jcf.2025.07.013

BibTeX
@article{Haskett2025,
  author = {Haskett, Haley and Fortner, Christopher and Shanley, Laura and Ren, Clement L},
  title = {Elevated serum lipase in infants with cystic fibrosis exposed to prenatal and postnatal elexacaftor/tezacaftor/ivacaftor},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  volume = {24},
  number = {6},
  pages = {1090--1093},
  doi = {10.1016/j.jcf.2025.07.013}
}
Kostenlos starten →